These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 9345401)
1. Guidelines for early treatment trials in patients presenting with clinical and paraclinical abnormalities which put them at high risk for conversion to multiple sclerosis. European Charcot Foundation Working Group for Treatment Trials. Mult Scler; 1995; 1 Suppl 1():S55-9. PubMed ID: 9345401 [TBL] [Abstract][Full Text] [Related]
2. Early treatment. Comi G Neurol Sci; 2006 Mar; 27 Suppl 1():S8-12. PubMed ID: 16708191 [TBL] [Abstract][Full Text] [Related]
3. Early treatment of multiple sclerosis with Rebif (recombinant human interferon beta): design of the study. Comi G; Barkhof F; Durelli L; Edan G; Fernandez O; Filippi M; Hartung HP; Hommes OR; Seeldrayers P; Soelberg-Sorensen P Mult Scler; 1995; 1 Suppl 1():S24-7. PubMed ID: 9345394 [TBL] [Abstract][Full Text] [Related]
4. Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Goodin DS; Bates D Mult Scler; 2009 Oct; 15(10):1175-82. PubMed ID: 19737851 [TBL] [Abstract][Full Text] [Related]
5. Disease-modifying drugs for the early treatment of multiple sclerosis. Flachenecker P Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542 [TBL] [Abstract][Full Text] [Related]
6. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience. Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353 [TBL] [Abstract][Full Text] [Related]
7. Early interferon beta treatment in multiple sclerosis: nursing care implications of the BENEFIT study. Webb UH J Neurosci Nurs; 2008 Dec; 40(6):356-61. PubMed ID: 19170303 [TBL] [Abstract][Full Text] [Related]
9. [Rationale for an early treatment of multiple sclerosis]. Comi G; Martino G Rev Neurol; 2000 Jun 16-30; 30(12):1265-8. PubMed ID: 10935262 [TBL] [Abstract][Full Text] [Related]
10. The effect of interferon-beta1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis. Motamed MR; Najimi N; Fereshtehnejad SM Clin Neurol Neurosurg; 2007 May; 109(4):344-9. PubMed ID: 17300863 [TBL] [Abstract][Full Text] [Related]
13. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Schwid SR; Panitch HS Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202 [TBL] [Abstract][Full Text] [Related]
14. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta. Comi G Clin Ther; 2009 Jun; 31(6):1142-57. PubMed ID: 19695384 [TBL] [Abstract][Full Text] [Related]
15. Repeated intervals of high-dose corticosteroid: an overlooked therapy in multiple sclerosis. Johnson LN; Morey SS Mo Med; 2005; 102(1):47-50. PubMed ID: 15754617 [TBL] [Abstract][Full Text] [Related]
17. [Treatment with beta-interferon should be started already after the first attack of MS]. Söderström M Lakartidningen; 2001 Feb; 98(6):587-90, 593-4. PubMed ID: 11475246 [No Abstract] [Full Text] [Related]
18. Adherence to interferon-beta treatment and results of therapy switching. Clerico M; Barbero P; Contessa G; Ferrero C; Durelli L J Neurol Sci; 2007 Aug; 259(1-2):104-8. PubMed ID: 17376486 [TBL] [Abstract][Full Text] [Related]